Fireside Chat: Getting to Yes in 2025 — Inside the Deals Fueling Pipelines and Promise

Session details:

Against the backdrop of this year’s selective biotech dealmaking environment, two transactions stood apart: Nurix’s $400M+ licensing deal with Sanofi and Regulus’ $1.7B acquisition by Novartis. What made these possible, and what can the rest of the industry learn from how they were done?

In this fast-paced, interactive fireside chat, biotech veteran Dr. John “Chip” Scarlett sits down with the dealmakers behind each transaction to explore how reputation, capabilities, and scientific or clinical outcomes helped these companies stand out.

What You’ll Take Away: 

- A sharper view into how two very different deals got done
- Real-world insight into shaping your strategy for partnership or M&A
- Key considerations in navigating negotiations within different deal structures 
- A chance to learn from—and ask questions of—leaders who’ve been through it

This isn’t a case study review, it’s a focused conversation that surfaces timely, transferable lessons from two of 2025’s most talked-about biotech deals.